New autoantibodies for rheumatoid arthritis: The autoantibodies that recognize posttranslationally modified self-proteins;Les nouveaux auto-anticorps de la polyarthrite rhumatoïde : des anticorps qui reconnaissent des proteínes du soi ayant subi des modifications post-translationnelles

Revue du Rhumatisme (Edition Francaise)

Volumn 83, Issue 1, 2016, Pages 12-18

  Cantagrel, Alain ^a   Degboe, Yannick ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

HUMAN; IMMUNOLOGY; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84987815171     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.10.003     Document Type: Short Survey

References (89)

1. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracyof anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheu-matoid arthritis. Ann Intern Med 2007;146:797-808.
2. Vincent C, Simon M, Sebbag M, et al. Immunoblotting detection of autoanti-bodies to human epidermis filaggrin: a new diagnostic test for rheumatoidarthritis. J Rheumatol 1998;25:838-46.
3. Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-calledantikeratin antibodies are the same rheumatoid arthritis-specific autoantibo-dies. J Clin Invest 1995;95:2672-9.
4. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essentialconstituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
5. Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinatedproteins gives the first clues to the etiology of rheumatoid arthritis. ImmunolRev 2010;233:34-54.
6. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by therheumatoid arthritis-associated antifilaggrin autoantibodies are posttransla-tionally generated on various sites of (pro)filaggrin by deimination of arginineresidues. J Immunol 1999;162:585-94.
7. Foulquier C, Sebbag M, Clavel C, et al. Peptidyl arginine deiminase type 2(PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheuma-toid arthritis synovium in close association with tissue inflammation. ArthritisRheum 2007;56:3541-53.
8. Nesse W, Westra J, van der Wal JE, et al. The periodontium of periodontitispatients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation. J Clin Periodontol 2012;39:599-607.
9. Wegner N, Wait R, Sroka A, et al. Peptidylarginine deiminase from Porphyromo-nas gingivalis citrullinates human fibrinogen and alpha-enolase: implicationsfor autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010;62:2662-72.
10. Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginineto citrulline allows for a high-affinity peptide interaction with the rheuma-toid arthritis-associated HLA-DRB1 0401 MHC class II molecule. J Immunol2003;171:538-41.
11. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining thecomplex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum2005;52:3433-8.
12. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cycliccitrullinated peptide antibodies and are not an independent risk factor fordevelopment of rheumatoid arthritis. Arthritis Rheum 2006;54:1117-21.
13. Haj Hensvold A, Magnusson PK, Joshua V, et al. Environmental and geneticfactors in the development of anticitrullinated protein antibodies (ACPAs) andACPA-positive rheumatoid arthritis: an epidemiological investigation in twins.Ann Rheum Dis 2013.
14. Aggarwal R, Liao K, Nair R, et al. Anti-citrullinated peptide antibody assaysand their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum2009;61:1472-83.
15. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classificationcriteria: an American College of Rheumatology/European League Against Rheu-matism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
16. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracyand prognostic value of the first and second anti-cyclic citrullinated peptides(CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis2005;64:1510-2.
17. van Venrooij WJ, Zendman AJ. Anti-CCP2 antibodies: an overview and perspec-tive of the diagnostic abilities of this serological marker for early rheumatoidarthritis. Clin Rev Allergy Immunol 2008;34:36-9.
18. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodiesprecede the symptoms of rheumatoid arthritis: a study of serial measurementsin blood donors. Arthritis Rheum 2004;50:380-6.
19. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cycliccitrullinated peptide and IgA rheumatoid factor predict the development ofrheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
20. Gossec L, Paternotte S, Combe B, et al. Repeated anticitrullinated protein anti-body and rheumatoid factor assessment is not necessary in early arthritis:results from the ESPOIR cohort. J Rheumatol 2014;41:41-6.
21. Barra L, Pope J, Bessette L, et al. Lack of seroconversion of rheumatoid factor andanti-cyclic citrullinated peptide in patients with early inflammatory arthritis:a systematic literature review. Rheumatology 2011;50:311-6.
22. Ronnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated pro-tein/peptide antibodies (anti-CP) during 5-year follow-up in early rheumatoidarthritis: anti-CP status predicts worse disease activity and greater radiologicalprogression. Ann Rheum Dis 2005;64:1744-9.
23. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cycliccitrullinated peptides predict progression to rheumatoid arthritis in patientswith undifferentiated arthritis: a prospective cohort study. Arthritis Rheum2004;50:709-15.
24. Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritisin anti-CCP positive individuals with non-specific musculoskeletal symptoms:a prospective observational cohort study. Ann Rheum Dis 2014.
25. van de Stadt LA, Witte BI, Bos WH, et al. A prediction rule for the developmentof arthritis in seropositive arthralgia patients. Ann Rheum Dis 2013;72:1920-6.
26. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoidarthritis. Arthritis Rheum 2000;43:1831-5.
27. Ursum J, Nielen MM, van Schaardenburg D, et al. Antibodies to mutated citrul-linated vimentin and disease activity score in early arthritis: a cohort study.Arthritis Res Ther 2008;10:R12.
28. Vencovsky J, Machacek S, Sedova L, et al. Autoantibodies can be prognosticmarkers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis2003;62:427-30.
29. Mouterde G, Lukas C, Goupille P, et al. Association of anticyclic citrullinatedpeptide antibodies and/or rheumatoid factor status and clinical presentationin early arthritis: results from the ESPOIR Cohort. J Rheumatol 2014.
30. Combe B, Rincheval N, Benessiano J, et al. Five-year favorable outcome ofpatients with early rheumatoid arthritis in the 2000s: data from the ESPOIRcohort. J Rheumatol 2013;40:1650-7.
31. Forslind K, Ahlmen M, Eberhardt K, et al. Prediction of radiological outcome inearly rheumatoid arthritis in clinical practice: role of antibodies to citrullinatedpeptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
32. Laurent L, Anquetil F, Clavel C, et al. IgM rheumatoid factor amplifies theinflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies.Ann Rheum Dis 2014.
33. Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiatorof anti-citrullinated protein antibody-mediated inflammation in rheumatoidarthritis. Arthritis Rheumatol 2014;66:813-21.
34. Hecht C, Englbrecht M, Rech J, et al. Additive effect of anti-citrullinated proteinantibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 2014.
35. Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and anti-body enrichment in the lungs are early features of anti-citrullinated proteinantibody-positive rheumatoid arthritis. Arthritis Rheumatol 2014;66:31-9.
36. Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoireexpansion of anticitrullinated peptide antibodies with rheumatoid arthritisassociated interstitial lung disease. Ann Rheum Dis 2014;73:1487-94.
37. Zhu J, Zhou Y, Chen X, et al. A metaanalysis of the increased risk of rheuma-toid arthritis-related pulmonary disease as a result of serum anticitrullinatedprotein antibody positivity. J Rheumatol 2014;41:1282-9.
38. Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor andanticitrullinated peptide antibody serotype on rituximab clinical response: ameta-analysis. Ann Rheum Dis 2013;72:329-36.
39. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituxi-mab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled datafrom 10 European registries. Ann Rheum Dis 2011;70:1575-80.
40. Gardette A, Ottaviani S, Tubach F, et al. High anti-CCP antibody titres predictgood response to rituximab in patients with active rheumatoid arthritis. JointBone Spine 2014.
41. Lv Q, Yin Y, Li X, et al. The status of rheumatoid factor and anti-cyclic citrul-linated peptide antibody are not associated with the effect of anti-TNFalphaagent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoSOne 2014;9:e89442.
42. Pers YM, Fortunet C, Constant E, et al. Predictors of response and remissionin a large cohort of rheumatoid arthritis patients treated with tocilizumab inclinical practice. Rheumatology 2014;53:76-84.
43. Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinatedpeptide is associated with a better response to abatacept: data from the 'Orenciaand Rheumatoid Arthritis' registry. Ann Rheum Dis 2012;71:1815-9.
44. Seegobin SD, Ma MH, Dahanayake C, et al. ACPA-positive and ACPA-negativerheumatoid arthritis differ in their requirements for combination DMARDs andcorticosteroids: secondary analysis of a randomized controlled trial. ArthritisRes Ther 2014;16:R13.
45. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major syno-vial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodiesare deiminated forms of the alpha-and beta-chains of fibrin. J Immunol2001;166:4177-84.
46. Cornillet M, Sebbag M, Verrouil E, et al. The fibrin-derived citrullinated pep-tide beta60-74Cit(6)(0),(7)(2),(7)(4) bears the major ACPA epitope recognisedby the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodiesand anti-CCP2 antibodies. Ann Rheum Dis 2014;73:1246-52.
47. Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Saantibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:R142-50.
48. Burkhardt H, Sehnert B, Bockermann R, et al. Humoral immune response tocitrullinated collagen type II determinants in early rheumatoid arthritis. Eur JImmunol 2005;35:1643-52.
49. Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated anti-gens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum2010;62:44-52.
50. Haag S, Schneider N, Mason DE, et al. Identification of new citrulline-specificautoantibodies, which bind to human arthritic cartilage, by mass spectrome-tric analysis of citrullinated type II collagen. Arthritis Rheumatol 2014;66:1440-9.
51. Chang X, Yamada R, Suzuki A, et al. Citrullination of fibronectin in rheumatoidarthritis synovial tissue. Rheumatology 2005;44:1374-82.
52. Kimura E, Kanzaki T, Tahara K, et al. Identification of citrullinated cellularfibronectin in synovial fluid from patients with rheumatoid arthritis. ModRheumatol 2014.
53. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther2005;7:R1421-9.
54. Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to theglycolytic enzyme alpha-enolase in sera from patients with early rheumatoidarthritis. Arthritis Rheum 2002;46:1196-201.
55. Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolasepeptide 1 are specific for rheumatoid arthritis and cross-react with bacterialenolase. Arthritis Rheum 2008;58:3009-19.
56. Shoda H, Fujio K, Shibuya M, et al. Detection of autoantibodies to citrullinatedBiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinatedBiP in collagen-induced arthritis. Arthritis Res Ther 2011;13:R191.
57. Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinatedhsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated inter-stitial lung disease. Arthritis Rheum 2013;65:869-79.
58. Pratesi F, Dioni I, Tommasi C, et al. Antibodies from patients with rheumatoidarthritis target citrullinated histone 4 contained in neutrophils extracellulartraps. Ann Rheum Dis 2014;73:1414-22.
59. Umeda N, Matsumoto I, Ito I, et al. Anti-citrullinated glucose-6-phosphate iso-merase peptide antibodies in patients with rheumatoid arthritis are associatedwith HLA-DRB1 shared epitope alleles and disease activity. Clin Exp Immunol2013;172:44-53.
60. Goeb V, Thomas-L'Otellier M, Daveau R, et al. Candidate autoantigens identi-fied by mass spectrometry in early rheumatoid arthritis are chaperones andcitrullinated glycolytic enzymes. Arthritis Res Ther 2009;11:R38.
61. Fhied C, Kanangat S, Borgia JA. Development of a bead-based immunoassay toroutinely measure vimentin autoantibodies in the clinical setting. J ImmunolMethods 2014;407:9-14.
62. Wagner CA, Sokolove J, Lahey LJ, et al. Identification of anticitrullinated pro-tein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis:association with cigarette smoking and HLA-DRB1 'shared epitope' alleles. Ann Rheum Dis 2014.
63. Diaz-Toscano ML, Olivas-Flores EM, Zavaleta-Muniz SA, et al. Compari-son of two assays to determine anti-citrullinated peptide antibodies inrheumatoid arthritis in relation to other chronic inflammatory rheumaticdiseases: assaying anti-modified citrullinated vimentin antibodies adds valueto second-generation anti-citrullinated cyclic peptides testing. BioMed Res Int2014;2014:198198.
64. Vander Cruyssen B, Cantaert T, Nogueira L, et al. Diagnostic value ofanti-human citrullinated fibrinogen ELISA and comparison with four otheranti-citrullinated protein assays. Arthritis Res Ther 2006;8:R122.
65. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmentaldeterminants for disease risk in subsets of rheumatoid arthritis defined by theanticitrullinated protein/peptide antibody fine specificity profile. Ann RheumDis 2013;72:652-8.
66. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheu-matoid arthritis: smoking may trigger HLA-DR (shared epitope)-restrictedimmune reactions to autoantigens modified by citrullination. Arthritis Rheum2006;54:38-46.
67. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading inthe pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One2012;7:e35296.
68. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and boneloss by human autoantibodies against citrullinated vimentin. J Clin Invest2012;122:1791-802.
69. Fisher BA, Plant D, Brode M, et al. Antibodies to citrullinated alpha-enolasepeptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2011;70:1095-8.
70. Scherer HU, van der Woude D, Willemze A, et al. Distinct ACPA fine speci-ficities, formed under the influence of HLA shared epitope alleles, have noeffect on radiographic joint damage in rheumatoid arthritis. Ann Rheum Dis2011;70:1461-4.
71. Montes A, Perez-Pampin E, Calaza M, et al. Association of anti-citrullinatedvimentin and anti-citrullinated alpha-enolase antibodies with subsets of rheu-matoid arthritis. Arthritis Rheum 2012;64:3102-10.
72. Avdeeva AS, Aleksandrova EN, Novikov AA, et al. The relationship of antibodiesto modified citrullinated vimentin and markers of bone and cartilage destruc-tion in rheumatoid arthritis. Int J Rheumatol 2014;2014:464-585.
73. Nicaise-Roland P, Nogueira L, Demattei C, et al. Autoantibodies to citrullinatedfibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosingrheumatoid arthritis at an early stage: data from the French ESPOIR cohort.Ann Rheum Dis 2013;72:357-62.
74. Wynckel A, Randoux C, Millart H, et al. Kinetics of carbamylated haemoglobinin acute renal failure. Nephrol Dial Transplant 2000;15:1183-8.
75. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflamma-tion, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-84.
76. Mydel P, Wang Z, Brisslert M, et al. Carbamylation-dependent activation ofT cells: a novel mechanism in the pathogenesis of autoimmune arthritis. JImmunol 2010;184:6882-90.
77. Scinocca M, Bell DA, Racape M, et al. Antihomocitrullinated fibrinogen anti-bodies are specific to rheumatoid arthritis and frequently bind citrullinatedproteins/peptides. J Rheumatol 2014;41:270-9.
78. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylatedproteins are present in sera of patients with rheumatoid arthritis and predictjoint damage. Proc Natl Acad Sci USA 2011;108:17372-7.
79. Jiang X, Trouw LA, van Wesemael TJ, et al. Anti-CarP antibodies in two largecohorts of patients with rheumatoid arthritis and their relationship to gene-tic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis2014;73:1761-8.
80. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein antibodiesare present in arthralgia patients and predict the development of rheumatoidarthritis. Arthritis Rheum 2013;65:911-5.
81. Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis2014;73:780-3.
82. Winyard PG, Moody CJ, Jacob C. Oxidative activation of antioxidant defence.Trends Biochem Sci 2005;30:453-61.
83. Mulherin DM, Thurnham DI, Situnayake RD. Glutathione reductase activity,riboflavin status, and disease activity in rheumatoid arthritis. Ann Rheum Dis1996;55:837-40.
84. Halliwell B, Oxygen radicals. nitric oxide and human inflammatory jointdisease. Ann Rheum Dis 1995;54:505-10.
85. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species inhomeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003;11:747-55.
86. Dalle-Donne I, Rossi R, Giustarini D, et al. Protein carbonyl groups as biomarkersof oxidative stress. Clin Chim Acta 2003;329:23-38.
87. Griffiths HR. Is the generation of neo-antigenic determinants by free radicalscentral to the development of autoimmune rheumatoid disease Autoimmun Rev 2008;7:544-9.
88. Nissim A, Winyard PG, Corrigall V, et al. Generation of neoantigenic epitopesafter posttranslational modification of type II collagen by factors present withinthe inflamed joint. Arthritis Rheum 2005;52:3829-38.
89. Strollo R, Ponchel F, Malmstrom V, et al. Autoantibodies to posttranslationallymodified type II collagen as potential biomarkers for rheumatoid arthritis.Arthritis Rheum 2013;65:1702-12.